BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19528470)

  • 21. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
    Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
    Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1.
    Ehata S; Hanyu A; Hayashi M; Aburatani H; Kato Y; Fujime M; Saitoh M; Miyazawa K; Imamura T; Miyazono K
    Cancer Res; 2007 Oct; 67(20):9694-703. PubMed ID: 17942899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
    Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
    Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
    Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
    Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
    Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
    Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
    Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
    Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A recombinant adeno-associated virus expressing secretory TGF-β type Ⅱ receptor inhibits triple-negative murine breast cancer 4T1 cell proliferation and lung metastasis in mice].
    Cui Z; Ma C; Wang Q; Chen J; Yan Z; Yang J; Lü Y; Cao C
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 May; 44(5):818-826. PubMed ID: 38862439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
    Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
    Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase.
    Buijs JT; Matula KM; Cheung H; Kruithof-de Julio M; van der Mark MH; Snoeks TJ; Cohen R; Corver WE; Mohammad KS; Jonkers J; Guise TA; van der Pluijm G
    J Pathol; 2015 Apr; 235(5):745-59. PubMed ID: 25421310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo.
    Du S; Bouquet S; Lo CH; Pellicciotta I; Bolourchi S; Parry R; Barcellos-Hoff MH
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):91-9. PubMed ID: 25835621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
    Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
    Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
    Kim EJ; Hong JE; Eom SJ; Lee JY; Park JH
    Breast Cancer Res Treat; 2011 Nov; 130(1):61-71. PubMed ID: 21170677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
    Bandyopadhyay A; Agyin JK; Wang L; Tang Y; Lei X; Story BM; Cornell JE; Pollock BH; Mundy GR; Sun LZ
    Cancer Res; 2006 Jul; 66(13):6714-21. PubMed ID: 16818646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.
    Connolly EC; Saunier EF; Quigley D; Luu MT; De Sapio A; Hann B; Yingling JM; Akhurst RJ
    Cancer Res; 2011 Mar; 71(6):2339-49. PubMed ID: 21282335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
    Ehata S; Hanyu A; Fujime M; Katsuno Y; Fukunaga E; Goto K; Ishikawa Y; Nomura K; Yokoo H; Shimizu T; Ogata E; Miyazono K; Shimizu K; Imamura T
    Cancer Sci; 2007 Jan; 98(1):127-33. PubMed ID: 17129361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
    Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
    J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
    Wallace A; Kapoor V; Sun J; Mrass P; Weninger W; Heitjan DF; June C; Kaiser LR; Ling LE; Albelda SM
    Clin Cancer Res; 2008 Jun; 14(12):3966-74. PubMed ID: 18559619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.